A 28-year-old woman with newly diagnosed smear-positive pulmonary TB is started on HRZE regimen. She is on oral contraceptives for menstrual regulation. After 1 week of TB therapy, she reports breakthrough bleeding and asks about contraceptive efficacy. What is the most appropriate next step?

Explanation

## Drug–Drug Interaction: Rifampicin and Oral Contraceptives ### Mechanism of Interaction **Key Point:** Rifampicin is a potent inducer of hepatic cytochrome P450 enzymes (especially CYP3A4), which dramatically increases the metabolism of ethinyl estradiol and progestins, reducing their serum concentrations by 40–60%. ### Clinical Consequences | Effect | Mechanism | Clinical Significance | |--------|-----------|----------------------| | Reduced OCP efficacy | ↑ Metabolism of estrogen/progestin | Contraceptive failure risk | | Breakthrough bleeding | Subtherapeutic hormone levels | Early warning sign of reduced efficacy | | Unintended pregnancy | Loss of ovulation suppression | Documented risk during TB treatment | **High-Yield:** Breakthrough bleeding during TB therapy in a woman on OCPs is a red flag for reduced contraceptive efficacy due to rifampicin-induced metabolism. ## Management Algorithm ```mermaid flowchart TD A["Woman on OCP starting TB therapy<br/>with rifampicin"]:::outcome A --> B{"Breakthrough bleeding or<br/>counseling needed?"}:::decision B -->|Yes| C["Counsel on reduced OCP efficacy"]:::action C --> D["Options:"]:::action D --> E["1. Switch to non-hormonal method<br/>(IUD, barrier)"]:::action D --> F["2. Continue OCP + barrier method<br/>(dual protection)"]:::action D --> G["3. Use higher-dose OCP<br/>(if available, though not ideal)"]:::action E --> H["Most reliable during TB treatment"]:::outcome F --> I["Acceptable if IUD/barrier declined"]:::outcome G --> J["Not recommended; increased<br/>side effects"]:::urgent ``` ## Recommended Approach **Clinical Pearl:** The breakthrough bleeding is a clinical warning sign that the OCP is no longer providing adequate contraceptive coverage. The patient should be counseled that: 1. **Discontinue OCPs** or accept significantly reduced efficacy 2. **Switch to non-hormonal methods:** - Intrauterine device (copper or levonorgestrel-releasing) — most reliable - Barrier methods (condoms) — acceptable but user-dependent - Combination approach (OCP + barrier) — compromise option 3. **Duration:** Continue alternative method throughout TB treatment (6 months) and for 4 weeks after rifampicin discontinuation (until enzyme induction resolves) **Warning:** Increasing the OCP dose is not recommended because: - Efficacy is not reliably restored - Risk of thromboembolism and other side effects increases - Documented contraceptive failures occur even with higher-dose OCPs during rifampicin use [cite:KD Tripathi 8e Ch 48; Harrison 21e Ch 205]